Physician profile
Cheyenne Clayson
NPI 1306339197
$8,359.72
in general payments reported to CMS, 2019-2025
30 companies · $2,511 in 2025
The $2,511 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,458 · 2022: $1,073 · 2023: $1,240 · 2024: $2,078 · 2025: $2,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,806 · Education: $22.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,806.27 |
| Education | $22.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,998.15 | 2021-2025 | |
| Gilead Sciences, INC. | $1,197.41 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $921.93 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $754.31 | 2021-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $685.44 | 2021-2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $423.39 | 2022-2025 | Dupixent |
| Genzyme Corporation | $411.74 | 2022-2025 | |
| Qol Medical, LLC | $255.53 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $208.28 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $190.54 | 2025 | Rezdiffra |
| Pfizer INC. | $178.76 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $125.59 | 2021-2024 | Ocaliva |
| Ardelyx, INC. | $117.25 | 2023-2024 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $114.14 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $98.91 | 2024-2025 | Vowst, Zenpep |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $92.25 | 2023-2025 | Rebyota |
| Daiichi Sankyo INC. | $74.19 | 2022-2024 | Injectafer |
| Janssen Scientific Affairs, LLC | $72.56 | 2021 | |
| Lilly USA, LLC | $64.98 | 2025 | Omvoh |
| Fresenius Kabi USA, LLC | $63.09 | 2023 | Idacio |
| Enterra Medical, INC. | $49.76 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $44.37 | 2021-2022 | |
| Organon LLC | $40.19 | 2024-2025 | Hadlima, Renflexis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.99 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $33.29 | 2023-2024 | Linzess |
| Redhill Biopharma INC. | $30.43 | 2021-2022 | |
| Celltrion USA INC. | $22.56 | 2023 | Yuflyma, Zymfentra |
| Mirum Pharmaceuticals, INC. | $21.12 | 2025 | Livmarli |
| Lucid Diagnostics INC. | $18.29 | 2023 | |
| Phathom Pharmaceuticals, INC. | $13.28 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheyenne Clayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.